TABLE 2.

Modifications in ITx practices during the study period 2003–2020

Year
2008
	Pre-ITx recipient screening for preformed anti-HLA antibodies by single-antigen assay.
	Virtual cross-matching for identification of preformed, donor-specific anti-HLA antibodies.
	Substitution of induction immune suppression using basiliximab (postoperative d 0 and 4, 10–20 mg/dose), formerly for all ITx recipients, with rabbit antithymocyte globulin for sensitized ITx recipients defined by panel reactive anti-HLA antibody level >20% or positive crossmatch (postoperative d 0–4, 1.5 mg/kg/d).
2009
	Standardized inclusion of graft ileocecal valve and graft ascending/transverse colon.
	Loop in preference to Santulli ileostomy.
2012
	High-dose intravenous immunoglobulin, rituximab (anti-CD20 monoclonal antibody), and plasmapheresis immediately before and after ITx in HLA antibody-sensitized recipients.
	Monitoring for donor-specific anti-HLA antibodies arising de novo after ITx and treatment with intravenous immunoglobulin when present.

ITx, intestinal transplant.